Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes

Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus

(2015) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial

(2015) Shizuka Kaneko et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk

(2014) Elaine Chow et al.   DIABETES

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

(2014) Gregory R. Fulcher et al.   DIABETES CARE

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

(2014) Tim Heise et al.   Diabetes Therapy

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

(2013) H. W. Rodbard et al.   DIABETIC MEDICINE

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

(2012) Leo Niskanen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues

(2011) Allan Vaag et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Correlates of Insulin Injection Omission

(2010) M. Peyrot et al.   DIABETES CARE

The Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of Biphasic Insulin Aspart: A Randomized, Glucose Clamp, Crossover Study

(2008) T. Heise et al.   Diabetes Technology & Therapeutics

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE